📰 Davida Ramsay News
Davida Ramsay News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Davida Ramsay. Real-time updates on events, politics, business and more.
August 21, 2023
Shares of Savara Inc (NASDAQ:SVRA – Get Free Report) rose 6.2% during mid-day trading on Monday . The stock traded as high as $3.76 and last traded at $3.76. Approximately 89,684 shares were traded during trading, a decline of 78% from the average daily volume of 398,873 shares. The stock had previously closed at $3.54. […]
August 17, 2023
Savara Inc (NASDAQ:SVRA – Free Report) – Equities researchers at HC Wainwright raised their Q3 2023 earnings per share (EPS) estimates for Savara in a report released on Monday, August 14th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.07) per share for the quarter, up from their prior […]
August 16, 2023
Savara (NASDAQ:SVRA – Get Free Report) had its price target upped by equities research analysts at HC Wainwright from $3.00 to $6.00 in a note issued to investors on Monday, Marketbeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 55.44% from the company’s […]
July 14, 2023
Savara Inc (NASDAQ:SVRA – Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 2,120,000 shares, a growth of 193.0% from the June 15th total of 723,500 shares. Approximately 1.9% of the company’s stock are sold short. Based […]
May 27, 2023
Savara Inc (NASDAQ:SVRA – Get Rating) Director David A. Ramsay purchased 37,124 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was acquired at an average price of $2.63 per share, for a total transaction of $97,636.12. Following the purchase, the director now owns 2,201,142 shares in the […]
March 2, 2022
Hollencrest Capital Management grew its stake in shares of La Jolla Pharmaceutical (NASDAQ:LJPC – Get Rating) by 94.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,355 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 […]